ATE442843T1 - Verwendung von c-terminal modifizierter oxamyl dipeptide als inhibitoren von der ice/ced-3 familie von cystein proteasen - Google Patents

Verwendung von c-terminal modifizierter oxamyl dipeptide als inhibitoren von der ice/ced-3 familie von cystein proteasen

Info

Publication number: ATE442843T1
Authority: AT; Austria
Prior art keywords: ced; inhibitors; ice; family; terminal modified
Prior art date: 1998-07-02

Application number

AT06125650T

Other languages

English (en)

Inventor

Donald Karanewsky

Robert Ternansky

Original Assignee

Idun Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-02

Filing date

1999-07-01

Publication date

2009-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26784233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE442843(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-07-01 Application filed by Idun Pharmaceuticals Inc filed Critical Idun Pharmaceuticals Inc

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE442843T1 publication Critical patent/ATE442843T1/de

Links

108010016626 Dipeptides Proteins 0.000 title 1
102000035195 Peptidases Human genes 0.000 title 1
108091005804 Peptidases Proteins 0.000 title 1
239000004365 Protease Substances 0.000 title 1
101150055276 ced-3 gene Proteins 0.000 title 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
KZAUOCCYDRDERY-UITAMQMPSA-N methyl (1z)-2-(dimethylamino)-n-(methylcarbamoyloxy)-2-oxoethanimidothioate Chemical group CNC(=O)O\N=C(/SC)C(=O)N(C)C KZAUOCCYDRDERY-UITAMQMPSA-N 0.000 title 1
208000035473 Communicable disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000004968 inflammatory condition Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1
230000035899 viability Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3258—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3264—Esters with hydroxyalkyl compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT06125650T 1998-07-02 1999-07-01 Verwendung von c-terminal modifizierter oxamyl dipeptide als inhibitoren von der ice/ced-3 familie von cystein proteasen ATE442843T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9168998P	1998-07-02	1998-07-02
US09/177,549 US6197750B1 (en)	1998-07-02	1998-10-22	C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases

Publications (1)

Publication Number	Publication Date
ATE442843T1 true ATE442843T1 (de)	2009-10-15

Family

ID=26784233

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT06125650T ATE442843T1 (de)	1998-07-02	1999-07-01	Verwendung von c-terminal modifizierter oxamyl dipeptide als inhibitoren von der ice/ced-3 familie von cystein proteasen
AT99932211T ATE348096T1 (de)	1998-07-02	1999-07-01	C-terminal modifizierte oxamyl dipeptide als inhibitorse von der ice/ced-3 familie von cystein proteasen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT99932211T ATE348096T1 (de)	1998-07-02	1999-07-01	C-terminal modifizierte oxamyl dipeptide als inhibitorse von der ice/ced-3 familie von cystein proteasen

Country Status (22)

Country	Link
US (1)	US6197750B1 (de)
EP (2)	EP1091930B1 (de)
JP (1)	JP3815968B2 (de)
KR (1)	KR100804432B1 (de)
CN (1)	CN1159289C (de)
AT (2)	ATE442843T1 (de)
AU (1)	AU752339B2 (de)
BR (1)	BR9911675A (de)
CA (1)	CA2336474C (de)
CY (1)	CY1108088T1 (de)
DE (2)	DE69941440D1 (de)
DK (2)	DK1754475T3 (de)
ES (2)	ES2330663T3 (de)
HU (1)	HUP0102898A3 (de)
ID (1)	ID28263A (de)
IL (1)	IL140554A0 (de)
MX (1)	MXPA00013014A (de)
NO (1)	NO20006544L (de)
NZ (1)	NZ509025A (de)
PL (1)	PL207578B1 (de)
PT (1)	PT1091930E (de)
WO (1)	WO2000001666A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1647279A3 (de) *	1996-09-12	2006-04-26	Idun Pharmaceuticals, Inc.	Hemmung der Apoptose unter Verwendung von Inhibitoren der Interleukin-1 Beta converting Enzym (ICE)/CED-3 Familie
US6184210B1 (en) *	1997-10-10	2001-02-06	Cytovia, Inc.	Dipeptide apoptosis inhibitors and the use thereof
TWI243828B (en) *	1998-03-19	2005-11-21	Vertex Pharma	Inhibitors of caspases
US7053056B2 (en) *	1998-07-02	2006-05-30	Idun Pharmaceuticals, Inc.	C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6544951B2 (en)	1998-07-02	2003-04-08	Idun Pharmaceuticals, Inc.	C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6355618B1 (en)	1999-04-09	2002-03-12	Cytovia, Inc.	Caspase inhibitors and the use thereof
US6495522B1 (en)	1999-08-27	2002-12-17	Cytovia, Inc.	Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
KR20020058078A (ko) *	1999-12-03	2002-07-12	우에노 도시오	옥사디아졸 유도체 및 그 유도체를 유효 성분으로 하는 약제
US6790989B2 (en) *	2000-01-13	2004-09-14	Idun Pharmaceuticals, Inc.	Inhibitors of the ICE/ced-3 family of cysteine proteases
US6515173B1 (en)	2000-01-13	2003-02-04	Idun Pharmaceuticals, Inc.	Inhibitors of the ICE/ced-3 family of cysteine proteases
US6867299B2 (en) *	2000-02-24	2005-03-15	Hoffmann-La Roche Inc.	Oxamide IMPDH inhibitors
US6525024B1 (en)	2000-04-17	2003-02-25	Idun Pharmaceuticals, Inc.	Inhibitors of the ICE/ced-3 family of cysteine proteases
EP1276717A2 (de) *	2000-04-17	2003-01-22	Idun Pharmaceuticals, Inc.	Inhibitoren von der ice/ced-3 familie von cystein proteasen
PE20011350A1 (es)	2000-05-19	2002-01-15	Vertex Pharma	PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2002070544A2 (en) *	2001-03-02	2002-09-12	Idun Pharmaceuticals, Inc.	Methods, compositions and kits for preserving antigenicity
EP1465862A1 (de)	2002-01-17	2004-10-13	SmithKline Beecham Corporation	Cycloalkyl-ketoamiden derivate und ihre verwendung als cathepsin-k-inhibitoren
US7410956B2 (en) *	2002-02-11	2008-08-12	Vertex Pharmaceuticals Incorporated	Caspase inhibitor prodrugs
AU2003225088A1 (en) *	2002-04-19	2003-11-03	Vertex Pharmaceuticals Incorporated	Regulation of tnf-alpha
US6727241B2 (en) *	2002-06-12	2004-04-27	Chemocentryx	Anti-inflammatory compositions and methods of use
JP2006503852A (ja) *	2002-09-25	2006-02-02	ユニバーシティーオブロチェスター	抗癌薬としてのカスパーゼインヒビター
WO2004033397A2 (en) *	2002-10-09	2004-04-22	Activx Biosciences, Inc.	Activity-based probes, and methods of their preparation and use
PE20050159A1 (es) *	2003-05-27	2005-04-19	Vertex Pharma	Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
AU2003902704A0 (en) *	2003-05-29	2003-06-19	Crc For Waste Management And Pollution Control Limited Of Unsw	Process for producing a nanoscale zero-valent metal
WO2005023761A2 (en) *	2003-09-11	2005-03-17	Kemia, Inc.	Cytokine inhibitors
CA2545733A1 (en) *	2003-11-10	2005-05-26	Vertex Pharmaceuticals Incorporated	Methods for monitoring il-18
EP2399916B1 (de) *	2004-03-12	2014-12-10	Vertex Pharmaceuticals Incorporated	Verfahren und Zwischenprodukte zur Herstellung von Asparaginacetal-Caspase-Inhibitoren
CA2567080A1 (en)	2004-05-27	2005-12-15	Vertex Pharmaceuticals Incorporated	Ice inhibitors for the treatment of autoinflammatory diseases
ATE543803T1 (de)	2004-11-24	2012-02-15	Vertex Pharma	3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
MX2008000659A (es) *	2005-07-11	2008-03-13	Pfizer Ltd	Nueva combinacion de anticuerpo contra madcam y de inhibidor de caspasa antifibrotico.
CN101268084A (zh) *	2005-07-28	2008-09-17	沃泰克斯药物股份有限公司	天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物
CN103951583B (zh) *	2006-12-06	2016-01-06	科内图斯医药公司	一种抑制剂的结晶形式
WO2012061786A1 (en)	2010-11-05	2012-05-10	Brandeis University	Ice cleaved alpha-synuclein a biomarker
US9956260B1 (en)	2011-07-22	2018-05-01	The J. David Gladstone Institutes	Treatment of HIV-1 infection and AIDS
EP4218829A3 (de) *	2013-03-15	2023-08-16	The Board of Trustees of the Leland Stanford Junior University	Aktivitätsbasierte sondenverbindungen, zusammensetzungen und verfahren zur verwendung
JP2017515854A (ja)	2014-05-12	2017-06-15	クオナトウスファーマシューティカルズ，インコーポレイテッド	カスパーゼ阻害剤による慢性肝疾患の合併症の治療
WO2016144830A1 (en)	2015-03-06	2016-09-15	Concert Pharmaceuticals, Inc.	Deuterated emricasan
WO2017079566A1 (en)	2015-11-05	2017-05-11	Conatus Pharmaceuticals, Inc.	Caspase inhibitors for use in the treatment of liver cancer
CA3010286A1 (en)	2015-12-31	2017-07-06	Conatus Pharmaceuticals Inc.	Methods of using caspase inhibitors in treatment of liver disease
TW201739734A (zh) *	2016-05-11	2017-11-16	Chia Tai Tianqing Pharmaceutical Group Co Ltd	Caspase抑制劑及其藥物組合物、用途和治療方法
RU2019113150A (ru)	2016-10-05	2020-11-06	Новартис Аг	Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
JP6984909B2 (ja)	2016-12-23	2021-12-22	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	活性ベースのプローブ化合物、組成物、および使用方法
WO2018133870A1 (zh) *	2017-01-23	2018-07-26	正大天晴药业集团股份有限公司	作为Caspase抑制剂的联环化合物
WO2019174589A1 (zh) *	2018-03-13	2019-09-19	正大天晴药业集团股份有限公司	一种Caspase抑制剂的结晶
EP3814327A1 (de)	2018-06-29	2021-05-05	Histogen, Inc.	(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorphenoxy)pentansäure-derivate und verwandte verbindungen als caspase-inhibitoren zur behandlung kardiovaskulärer erkrankungen
WO2022123062A1 (en)	2020-12-11	2022-06-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
IL315185A (en) *	2022-02-25	2024-10-01	Carmel Haifa Univ Economic Corporation Ltd	Apoptosis related protein in the tgf-beta signaling pathway (arts) mimetic compounds, compositions, methods and uses thereof in induction of apoptosis
CN119529128B (zh) *	2024-11-21	2026-04-17	中国科学院昆明植物研究所	具有抗白血病活性的当归多糖aps-1 ii 13糖和子结构9糖的制备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6204261B1 (en) *	1995-12-20	2001-03-20	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β Converting enzyme inhibitors
EP0618223A3 (de) *	1993-03-08	1996-06-12	Sandoz Ltd	Peptide, die Freisetzung vom Interleukin 1-Bêta, nützlich als entzündungshemmende Wirkstoffe.
CA2122227A1 (en)	1993-04-29	1994-10-30	Roland E. Dolle	Peptide analogs as irreversible interleukin-1.beta. protease inhibitors
US5869519A (en) *	1996-12-16	1999-02-09	Idun Pharmaceuticals, Inc.	C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) *	1996-09-20	1999-10-19	Idun Pharmaceuticals, Inc.	Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US5877197A (en) *	1996-12-16	1999-03-02	Karanewsky; Donald S.	C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases

1998
- 1998-10-22 US US09/177,549 patent/US6197750B1/en not_active Expired - Lifetime
1999
- 1999-07-01 AT AT06125650T patent/ATE442843T1/de not_active IP Right Cessation
- 1999-07-01 ES ES06125650T patent/ES2330663T3/es not_active Expired - Lifetime
- 1999-07-01 EP EP99932211A patent/EP1091930B1/de not_active Expired - Lifetime
- 1999-07-01 CN CNB998100196A patent/CN1159289C/zh not_active Expired - Lifetime
- 1999-07-01 WO PCT/US1999/015074 patent/WO2000001666A1/en not_active Ceased
- 1999-07-01 MX MXPA00013014A patent/MXPA00013014A/es active IP Right Grant
- 1999-07-01 HU HU0102898A patent/HUP0102898A3/hu unknown
- 1999-07-01 ID IDW20010254A patent/ID28263A/id unknown
- 1999-07-01 BR BR9911675-8A patent/BR9911675A/pt not_active IP Right Cessation
- 1999-07-01 CA CA002336474A patent/CA2336474C/en not_active Expired - Lifetime
- 1999-07-01 DE DE69941440T patent/DE69941440D1/de not_active Expired - Lifetime
- 1999-07-01 DE DE69934405T patent/DE69934405T2/de not_active Expired - Lifetime
- 1999-07-01 DK DK06125650T patent/DK1754475T3/da active
- 1999-07-01 AU AU48569/99A patent/AU752339B2/en not_active Expired
- 1999-07-01 PT PT99932211T patent/PT1091930E/pt unknown
- 1999-07-01 EP EP06125650A patent/EP1754475B1/de not_active Expired - Lifetime
- 1999-07-01 JP JP2000558071A patent/JP3815968B2/ja not_active Expired - Lifetime
- 1999-07-01 ES ES99932211T patent/ES2276520T3/es not_active Expired - Lifetime
- 1999-07-01 IL IL14055499A patent/IL140554A0/xx not_active IP Right Cessation
- 1999-07-01 AT AT99932211T patent/ATE348096T1/de active
- 1999-07-01 KR KR1020007015074A patent/KR100804432B1/ko not_active Expired - Lifetime
- 1999-07-01 DK DK99932211T patent/DK1091930T3/da active
- 1999-07-01 NZ NZ509025A patent/NZ509025A/en not_active Application Discontinuation
- 1999-07-01 PL PL345350A patent/PL207578B1/pl not_active IP Right Cessation
2000
- 2000-12-21 NO NO20006544A patent/NO20006544L/no unknown
2007
- 2007-02-22 CY CY20071100251T patent/CY1108088T1/el unknown

Also Published As

Publication number	Publication date
CN1159289C (zh)	2004-07-28
MXPA00013014A (es)	2004-04-02
IL140554A0 (en)	2002-02-10
CA2336474C (en)	2008-04-29
DE69941440D1 (de)	2009-10-29
WO2000001666A1 (en)	2000-01-13
KR20010083079A (ko)	2001-08-31
CY1108088T1 (el)	2014-02-12
HUP0102898A2 (hu)	2002-01-28
US6197750B1 (en)	2001-03-06
CN1313846A (zh)	2001-09-19
ES2276520T3 (es)	2007-06-16
PL345350A1 (en)	2001-12-17
PL207578B1 (pl)	2011-01-31
DE69934405T2 (de)	2007-10-31
PT1091930E (pt)	2007-02-28
BR9911675A (pt)	2002-02-05
ES2330663T3 (es)	2009-12-14
EP1754475B1 (de)	2009-09-16
KR100804432B1 (ko)	2008-02-20
DK1754475T3 (da)	2009-11-09
NO20006544L (no)	2001-02-28
EP1091930B1 (de)	2006-12-13
JP2002519406A (ja)	2002-07-02
JP3815968B2 (ja)	2006-08-30
CA2336474A1 (en)	2000-01-13
DK1091930T3 (da)	2007-04-02
DE69934405D1 (de)	2007-01-25
ATE348096T1 (de)	2007-01-15
EP1754475A1 (de)	2007-02-21
EP1091930A1 (de)	2001-04-18
ID28263A (id)	2001-05-10
NZ509025A (en)	2003-05-30
AU4856999A (en)	2000-01-24
HUP0102898A3 (en)	2002-09-30
HK1036616A1 (en)	2002-01-11
NO20006544D0 (no)	2000-12-21
AU752339B2 (en)	2002-09-19

Legal Events

Date	Code	Title	Description
2010-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE442843T1 (de)	2009-10-15	Verwendung von c-terminal modifizierter oxamyl dipeptide als inhibitoren von der ice/ced-3 familie von cystein proteasen
ATE193304T1 (de)	2000-06-15	Inhibitoren der menschlichen neutrophilenelastase
TR199901191T2 (xx)	1999-12-21	Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
ES2128283T1 (es)	1999-05-16	Profarmacos de inhibidores de trombina.
MY122696A (en)	2006-04-29	Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases.
ATE181925T1 (de)	1999-07-15	Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau
IL156774A0 (en)	2004-02-08	Inhibitors of cruzipain and other cysteine proteases
BG104885A (en)	2001-05-31	Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
FI970279A0 (fi)	1997-01-23	Orgaanisia yhdisteitä
AR021241A1 (es)	2002-07-03	Inhibidores de proteasas
ATE427653T1 (de)	2009-04-15	Stabilisierung der milch transgener tieren
BR9711540A (pt)	2001-06-19	Inibidores de protease proteìnico estabilizados e variantes dos mesmos
DE60040348D1 (de)	2008-11-06	R verwendung des diphtheria-toxins
BR9808210A (pt)	2000-05-16	Befeniloxazolinas dissubstituìdas
DE60203726D1 (de)	2005-05-19	Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
DE60007991D1 (de)	2004-03-04	Verwendung des proteins uk 114 zur verhinderung der abstossung eines transplantierten organs
ATE340569T1 (de)	2006-10-15	Verwendung eines neuen mittels zur verhütung von infektionen
ATE238781T1 (de)	2003-05-15	Verwendung von katecholderivaten als proteinaseinhibitoren
ECSP993018A (es)	1999-11-29	Nuevos inhibidores de proteasas, particularmente inhibidores de cisteina y serina proteasas